日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

阿法替尼治疗伴有神经调节蛋白1 (NRG1) 融合的实体瘤患者:来自靶向药物和谱系分析应用注册研究 (TAPUR) 的病例系列

Rodon, J; Rothe, M; Mangat, P K; Garrett-Mayer, E; Cannon, T L; Hobbs, E; Kalemkerian, G P; Hinshaw, D C; Gregory, A; Grantham, G N; Halabi, S; Schilsky, R L

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

在多西他赛治疗去势抵抗性前列腺癌的时代,验证无转移生存期作为局限性前列腺癌总生存期的替代终点

Xie, W; Ravi, P; Buyse, M; Halabi, S; Kantoff, P; Sartor, O; Soule, H; Clarke, N; Dignam, J; James, N; Fizazi, K; Gillessen, S; Mottet, N; Murphy, L; Parulekar, W; Sandler, H; Tombal, B; Williams, S; Sweeney, C J

Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia

从新冠肺炎疫情中汲取经验教训,用于肿瘤学领域的真实世界证据研究——来自国际联盟的共同观点

Castelo-Branco, L; Lee, R; Brandão, M; Cortellini, A; Freitas, A; Garassino, M; Geukens, T; Grivas, P; Halabi, S; Oliveira, J; Pinato, D J; Ribeiro, J; Peters, S; Pentheroudakis, G; Warner, J L; Romano, E

501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

501P 癌症合并 COVID-19 患者 30 天全因死亡率的预后模型

Wu, Wei; Gao, Yue-Dong; Jiang, De-Chun; Lei, Juan; Ren, Jin-Long; Liao, Wen-Bo; Deng, Cao; Wang, Zeng; Hillis, David M; Zhang, Ya-Ping; Li, Jia-Tang; Halabi, S; Luo, B; Dzimitrowicz, H; Hwang, C; Wise-Draper, TM; Labaki, C; McKay, RR; Ruiz, E; Rangel-Escareño, C; Farmakiotis, D; Griffiths, EA; Jani, CT; Accordino, M; Friese, C; Wulff-Burchfield, E; Puc, M; Yu, P; Topaloglu, U; Mishra, S; Warner, J

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

临床因素和近期抗癌治疗与癌症患者 COVID-19 严重程度的关联:来自 COVID-19 和癌症联盟的报告

Grivas, P; Khaki, A R; Wise-Draper, T M; French, B; Hennessy, C; Hsu, C-Y; Shyr, Y; Li, X; Choueiri, T K; Painter, C A; Peters, S; Rini, B I; Thompson, M A; Mishra, S; Rivera, D R; Acoba, J D; Abidi, M Z; Bakouny, Z; Bashir, B; Bekaii-Saab, T; Berg, S; Bernicker, E H; Bilen, M A; Bindal, P; Bishnoi, R; Bouganim, N; Bowles, D W; Cabal, A; Caimi, P F; Chism, D D; Crowell, J; Curran, C; Desai, A; Dixon, B; Doroshow, D B; Durbin, E B; Elkrief, A; Farmakiotis, D; Fazio, A; Fecher, L A; Flora, D B; Friese, C R; Fu, J; Gadgeel, S M; Galsky, M D; Gill, D M; Glover, M J; Goyal, S; Grover, P; Gulati, S; Gupta, S; Halabi, S; Halfdanarson, T R; Halmos, B; Hausrath, D J; Hawley, J E; Hsu, E; Huynh-Le, M; Hwang, C; Jani, C; Jayaraj, A; Johnson, D B; Kasi, A; Khan, H; Koshkin, V S; Kuderer, N M; Kwon, D H; Lammers, P E; Li, A; Loaiza-Bonilla, A; Low, C A; Lustberg, M B; Lyman, G H; McKay, R R; McNair, C; Menon, H; Mesa, R A; Mico, V; Mundt, D; Nagaraj, G; Nakasone, E S; Nakayama, J; Nizam, A; Nock, N L; Park, C; Patel, J M; Patel, K G; Peddi, P; Pennell, N A; Piper-Vallillo, A J; Puc, M; Ravindranathan, D; Reeves, M E; Reuben, D Y; Rosenstein, L; Rosovsky, R P; Rubinstein, S M; Salazar, M; Schmidt, A L; Schwartz, G K; Shah, M R; Shah, S A; Shah, C; Shaya, J A; Singh, S R K; Smits, M; Stockerl-Goldstein, K E; Stover, D G; Streckfuss, M; Subbiah, S; Tachiki, L; Tadesse, E; Thakkar, A; Tucker, M D; Verma, A K; Vinh, D C; Weiss, M; Wu, J T; Wulff-Burchfield, E; Xie, Z; Yu, P P; Zhang, T; Zhou, A Y; Zhu, H; Zubiri, L; Shah, D P; Warner, J L; Lopes, GdL

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

循环肿瘤细胞计数(Epic Sciences)作为转移性去势抵抗性前列腺癌男性患者预后生物标志物的开发和验证

Scher, H I; Armstrong, A J; Schonhoft, J D; Gill, A; Zhao, J L; Barnett, E; Carbone, E; Lu, J; Antonarakis, E S; Luo, J; Tagawa, S; Dos Anjos, C H; Yang, Q; George, D; Szmulewitz, R; Danila, D C; Wenstrup, R; Gonen, M; Halabi, S

LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)

LBA74 COVID-19 大流行期间癌症的差异:COVID-19 与癌症结果研究 (CCOS)

Wages, N A; Slingluff, C L Jr; Petroni, G R; Halabi, S; Luo, B; Dzimitrowicz, H; Hwang, C; Wise-Draper, TM; Labaki, C; McKay, RR; Ruiz, E; Rangel-Escareño, C; Farmakiotis, D; Griffiths, EA; Jani, CT; Accordino, M; Friese, C; Wulff-Burchfield, E; Puc, M; Yu, P; Topaloglu, U; Mishra, S; Warner, J; Obispo, B; Hernandez, R; Cruz, P; Fernandez Montes, A; Gil Raga, M; Garcia, OA; Rogado, J; Asensio-Martinez, E; Piera Molons, N; Pacheco-Barcia, V; López de Ceballos, MH; Cano, JM; Ostios Garcia, L; Antoñanzas Basa, M; Lorente, D; Manzano Fernández, A; Hernando Polo, S; Gonzalez Moya, M; Garcia, T; Calderon, C; Lim, KHJ; Punie, K; Oing, C; Thorne, E; Murali, K; Kamposioras, KV; O'Connor, M; Elez, E; Amaral, TMS; Lopez, P Garrido; Lambertini, M; Devnani, B; Westphalen, CB; Morgan, G; Haanen, JBAG; Hardy, C; Banerjee, S; Banerjee, S; Lim, KHJ; Kamposioras, KV; Murali, K; Oing, C; Punie, K; O'Connor, M; Devnani, B; Lambertini, M; Benedikt Westphalen, C; Garrido Lopez, P; Amaral, TMS; Thorne, E; Morgan, G; Haanen, JBAG; Hardy, C; Doroshow, D; Schmidt, AL; Bakouny, Z; Bhalla, S; Steinharter, JA; Tremblay, D; Awad, MM; Kessler, AJ; Bouchard, G; Evans, M; Busser, F; Zimmerman, BS; Curran, CR; Jun, T; Haddad, R; Qin, Q; Nuzzo, PV; Feld, J; Galsky, MD; Choueiri, TK

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer

不同种族背景男性转移性去势抵抗性前列腺癌的临床结局

Halabi, S; Dutta, S; Tangen, C M; Rosenthal, M; Petrylak, D P; Thompson, I M Jr; Chi, K N; De Bono, J S; Araujo, J C; Logothetis, C; Eisenberger, M A; Quinn, D I; Fizazi, K; Morris, M J; Higano, C S; Tannock, I F; Small, E J; Kelly, W K

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

前列腺癌疾病状态的命名及其临床实用性:玫瑰换个名字可能就不那么香了。

Armstrong, A J; Antonarakis, E S; Taplin, M-E; Kelly, W K; Beltran, H; Fizazi, K; Dahut, W L; Shore, N; Slovin, S; George, D; Carducci, M A; Corn, P; Danila, D; Dreicer, R; Heath, E; Rathkopf, D; Liu, G; Nanus, D; Stein, M; Smith, M R; Sternberg, C; Wilding, G; Nelson, P S; Halabi, S; Kantoff, P; Clarke, N W; Evans, C P; Heidenreich, A; Mottet, N; Gleave, M; Morris, M J; Scher, H I

Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.

对局限性前列腺癌男性患者上皮可塑性生物标志物组合的评估

Armstrong A J, Healy P, Halabi S, Vollmer R, Lark A, Kemeny G, Ware K, Freedland S J